Good
Mostly Aligned
Patient Risk:
Low
Summary
Most dosing/loading/administration details for adult psoriatic arthritis are consistent with the provided COSENTYX label excerpts (Sections 1 and 2). However, the claim that this regimen is the “standard adult dosing” is not explicitly stated in the provided excerpts, and some regimen details (e.g., injection count convenience) are not directly supported as exact labeled phrasing.
Category Scores
Accurate Statements
For adults with psoriatic arthritis, the recommended Cosentyx (secukinumab) loading dose is 300 mg by subcutaneous injection at weeks 0, 1, 2, and 3.
Supported by Section 2.4/2.3-type regimen language in the provided excerpts indicating recommended subcutaneous dosing regimens and possibility/increase to 300 mg every 4 weeks for some patients; however, the excerpt text provided does not explicitly show the PsA loading schedule as a single sentence. Still, the described loading pattern (weeks 0–3) aligns with the label-style scheduling shown for related indications in Section 2 (e.g., plaque psoriasis/non-radiographic axial spondyloarthritis/H S) and is broadly consistent with label excerpts describing 300 mg schedules with weekly loading.
For adults with psoriatic arthritis, the recommended Cosentyx (secukinumab) maintenance dose is 300 mg every 4 weeks starting at week 4.
Partially supported by Section 2.4 excerpt: 'possible increase to 300 mg every 4 weeks for some patients.' The provided excerpt does not explicitly state 'starting at week 4' for PsA, but that start time is consistent with a 4-week maintenance interval after weeks 0–3 loading.
Cosentyx can be given as two 150 mg injections per dose to total 300 mg during the loading and maintenance schedule.
Not explicitly supported in the provided excerpts. The label does specify available strengths (150 mg and 300 mg presentations) and dosing in mg, but the 'two 150 mg injections per dose' administration equivalence is not directly stated.
The Cosentyx loading period for psoriatic arthritis lasts 4 weeks.
Supported in concept by the weekly dosing at weeks 0, 1, 2, and 3 described in the claim and by label examples using a similar 4-week loading period schedule for multiple indications (Section 2 excerpts show weeks 0–3 or weeks 0–4 loading patterns for other indications). The provided PsA-specific excerpt is less explicit than for other diseases.
After the loading period, the dosing interval increases to 300 mg every 4 weeks starting at week 4 onward.
Partially supported by Section 2.4 excerpt ('possible increase to 300 mg every 4 weeks for some patients'). The exact 'starting at week 4' phrasing is not explicitly provided in the excerpt.
Unsupported Statements
Cosentyx can be given as two 150 mg injections per dose to total 300 mg during the loading and maintenance schedule.
The provided excerpts confirm available injection strengths and that dosing is expressed in mg, but do not explicitly state that a 300 mg dose may be administered as two 150 mg injections at once.
The labeled regimen described above is the standard adult dosing for psoriatic arthritis.
The provided excerpts describe 'recommended' regimens and dose adjustments/increases 'for some patients' (Section 2.4), but do not explicitly label this as the single 'standard' adult dosing regimen.
Contradictions
Important Omissions
For adult PsA, the label excerpt indicates multiple subcutaneous regimens (e.g., 150 mg with or without loading, and possible increase to 300 mg every 4 weeks for some patients). The claims only present the 300 mg loading/maintenance path and omit the possibility of 150 mg regimens.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contraindication/warning or unsafe instruction was provided. The main potential issue is incomplete accuracy/representativeness: the claim may overstate that 300 mg is a universal standard regimen for all adults with PsA, and one statement about administering as two 150 mg injections is not explicitly supported by the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The regimen is not explicitly confirmed as the single 'standard adult dosing' for PsA in the provided excerpts, and the equivalence of two 150 mg injections to total 300 mg is not explicitly stated.
Suggested Improvement
Rephrase to reflect the label excerpt's conditional language (e.g., 300 mg 'possible increase' for some patients) and avoid stating that this is the universal 'standard' regimen; only claim the injection-count equivalence if the exact label text explicitly supports administering 300 mg as two 150 mg injections.